Filing Details

Accession Number:
0001209191-16-137674
Form Type:
4
Zero Holdings:
No
Publication Time:
2016-08-17 19:45:35
Reporting Period:
2016-08-15
Filing Date:
2016-08-17
Accepted Time:
2016-08-17 19:45:35
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1396814 Pacira Pharmaceuticals Inc. PCRX () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1383242 S James Scibetta C/O Pacira Pharmaceuticals, Inc.
5 Sylvan Way, Suite 300
Parsippany NJ 07054
President No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2016-08-15 9,123 $1.61 36,207 No 4 M Direct
Common Stock Acquisiton 2016-08-15 15,877 $1.61 52,084 No 4 M Direct
Common Stock Disposition 2016-08-15 25,000 $45.21 27,084 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2016-08-15 9,123 $0.00 9,123 $1.61
Common Stock Stock Option (Right to Buy) Disposition 2016-08-15 15,877 $0.00 15,877 $1.61
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2020-09-02 No 4 M Direct
22,373 2020-09-02 No 4 M Direct
Footnotes
  1. The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.
  2. Includes 330 shares of common stock acquired under the issuer's employee stock purchase plan in June 2016.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.82 to$45.76, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities andExchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth inthis footnote 2.
  4. The option vested as to 25% of the options on September 2, 2011 and vests as to the remaining options in successive equal monthly installments for the subsequent 36 months. The options became exercisable, to the extent vested, from and after the issuer's initial public offering.
  5. The option vested as to 50% of the options on September 2, 2010 and vests as to the remaining options in successive equal monthly installments for the subsequent 24 months. The options become exercisable, to the extent vested, from and after the issuer's initial public offering.